Clonal Evolution in Multiple Myeloma: Implications for Disease Progression and Resistance

Thomas Andrew^*
*Correspondence: Thomas Andrew, Department of Radiation Oncology, Washington University, Missouri, USA, Email:

Introduction

Multiple myeloma is a malignant disorder characterized by the uncontrolled proliferation of plasma cells in the bone marrow. Although therapeutic advances have led to significant improvements in survival, the disease remains incurable for the vast majority of patients. One of the most significant biological features contributing to this therapeutic challenge is clonal evolution. This dynamic process, whereby genetically distinct subpopulations of malignant cells emerge, expand, or diminish over time, plays a central role in disease progression, treatment failure, and eventual resistance. Understanding the mechanisms, patterns, and consequences of clonal evolution has therefore become a major focus in multiple myeloma research, with the aim of developing more effective treatment strategies and improving long-term outcomes [1].

Description

Clonal evolution refers to the sequential acquisition of genetic changes in tumor cells, resulting in the formation of multiple subclones that coexist within the same tumor microenvironment. In multiple myeloma, this evolutionary process begins early, often in precursor conditions such as monoclonal gammopathy of undetermined significance or smoldering multiple myeloma [2]. Even at these early stages, the malignant plasma cell population may not be genetically uniform, and the presence of distinct subclones may influence the risk of progression to symptomatic disease. As the disease advances, these subclones may acquire additional mutations, leading to a more genetically diverse tumor population. This diversity allows the tumor to adapt to selective pressures, including those imposed by therapy, the immune system, and the bone marrow environment [3].

Early insights into clonal evolution in multiple myeloma were derived from cytogenetic and fluorescence-based studies that identified chromosomal abnormalities associated with disease subtypes and prognosis. However, the advent of advanced sequencing technologies has provided a much more detailed view of the clonal architecture in multiple myeloma. Longitudinal studies analyzing samples from diagnosis, relapse, and progression have shown that the tumor evolves in a non-linear and often unpredictable fashion [4]. There are several models of clonal evolution observed in multiple myeloma. The linear model suggests that one dominant clone accumulates mutations over time, leading to a more aggressive phenotype. In contrast, the branching model proposes that multiple subclones evolve independently from a common ancestor, giving rise to significant heterogeneity. A third, more complex model, known as neutral evolution, implies that subclonal diversity arises without strong selective pressures, and that random mutations accumulate in parallel across multiple subclones [5].

Conclusion

In conclusion, clonal evolution is a fundamental biological process that underlies disease progression and therapeutic resistance in multiple myeloma. It reflects the capacity of malignant plasma cells to adapt and survive under selective pressures, leading to genetic diversity and dynamic changes in tumor behavior. Advances in genomic sequencing have revealed complex patterns of evolution, including linear, branching, and neutral models, each with distinct clinical implications. The presence of multiple subclones at diagnosis, the emergence of resistant clones during therapy, and the influence of the microenvironment all contribute to the challenges of managing this disease. Future strategies to combat multiple myeloma must incorporate an understanding of clonal dynamics, including the use of real-time genomic monitoring, combination therapies targeting multiple subclones, and novel approaches that disrupt the evolutionary potential of tumor cells. By embracing the complexity of clonal evolution, clinicians and researchers can move closer to achieving long-term disease control and ultimately, a cure for multiple myeloma.

Acknowledgment

None.

Conflict of Interest

None.

References

1. Rasmussen, Thomas, Jacob Haaber, Inger Marie Dahl and Lene M. Knudsen, et al. "Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma." Haematologica 95 (2010): 1730.

Google Scholar Cross Ref Indexed at

2. Ordoñez, Raquel, Marta Kulis, Nuria Russiñol and Vicente Chapaprieta, et al. "Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma." Genome Res 30 (2020): 1217-1227.

Google Scholar Cross Ref Indexed at

3. Beksac, Meral, Loren Gragert, Stephanie Fingerson and Martin Maiers, et al. "HLA polymorphism and risk of multiple myeloma." Leukemia30 (2016): 2260-2264.

Google Scholar Cross Ref Indexed at

4. Brousseau, Maud, Xavier Leleu, Jérémie Gerard and Thomas Gastinne, et al. "Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients." Clin Cancer Res 13 (2007): 6026-6031.

Google Scholar Cross Ref Indexed at

5. Magrangeas, F., L. Lode, S. Wuilleme and S. Minvielle, et al. "Genetic heterogeneity in multiple myeloma." Leukemia 19 (2005): 191-194.

Google Scholar Cross Ref Indexed at